Method, reagent strip and kit for marking human immunodeficiency virus recombinant antigen by colloidal gold

By first adding a small amount of BSA-1 to the colloidal gold labeling method, and then adding recombinant antigen and BSA-2 of human immunodeficiency virus, the non-specific reaction problem caused by supersaturation of antigens to be labeled in the prior art is solved, and the color development intensity and sensitivity of the product are improved.

CN119534840AInactive Publication Date: 2025-02-28WEIFANG GUARANTEE BIOLOGICAL TECH CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202510107480.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-01-23
Publication Date
2025-02-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the existing colloidal gold labeling methods, supersaturation addition of the antigen/antibody to be labeled will lead to a non-specific reaction, affecting the color development intensity and sensitivity of the product.

Method used

By first adding a small amount of bovine serum albumin (BSA-1) around the colloidal gold, then adding an appropriate amount of human immunodeficiency virus recombinant antigen, and finally adding the blocking agent BSA-2, the pH value is adjusted to ensure the stability and effectiveness of the labeling process.

Benefits of technology

This method not only reduces the amount of antigen/antibody to be labeled, avoids non-specific reactions of the vacant sites on the surface of colloidal gold, but also improves the color development intensity and sensitivity of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a method, a reagent strip and a kit for marking human immunodeficiency virus recombinant antigens by colloidal gold, and belongs to the technical field of gold immunization, the method for marking human immunodeficiency virus recombinant antigens by colloidal gold comprises the following steps: (1) preparing a colloidal gold solution; (2) adjusting the pH value of the prepared colloidal gold solution to 6.0; (3) adding a proper amount of BSA-1 solution at one time; (4) adjusting the pH value of the liquid obtained in the step (3) to 7.0-7.5; (5) adding the human immunodeficiency virus recombinant antigen at one time, wherein the adding amount is 55-65% of the using amount of the saturated labeled human immunodeficiency virus recombinant antigen; 6, a final sealing agent BSA-2 solution is added, and labeling is completed. The stability of the reagent strip can be guaranteed, the dosage of the antigen / antibody to be labeled is reduced, the situation that unoccupied sites exist on the surface of colloidal gold, and consequently non-specific reaction occurs can be avoided, and finally the developing intensity and sensitivity of a product can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of gold immunotechnology, and in particular relates to a method for labeling human immunodeficiency virus recombinant antigen with colloidal gold, a reagent strip and a kit. Background Art

[0002] Golden Immunotechnology is a technology of vital importance in the rapid diagnosis industry of contemporary medicine. It utilizes the characteristics of specific recognition of antigens and antibodies and stable binding of tracers to antigens / antibodies, making rapid diagnostic reagents widely used in common testing sites such as community clinics, schools, and customs, bringing great convenience to people's lives.

[0003] Gold immunoassay technology uses colloidal gold as a tracer, labels it with antigens / antibodies that can specifically bind to the substance to be tested, and adopts reaction principles such as double antigen sandwich method, double antibody sandwich method, competitive method, indirect method, etc., and finally assembles it into a reagent that can detect various substances to be tested.

[0004] Among them, the colloidal gold labeling method is the core control point of this technology. The conventional labeling method is to adjust the colloidal gold solution to the optimal reaction pH value of the antigen / antibody to be labeled, add a certain amount of the antigen / antibody to be labeled, and after sufficient reaction, add a blocking agent to block other reaction sites of the colloidal gold. The amount of the antigen / antibody to be labeled added in this method needs to be supersaturated to fully wrap around the colloidal gold, ensure the stability of the gold label solution, and prevent the vacant sites on the surface of the colloidal gold from non-specific reactions; however, when the amount of the antigen / antibody to be labeled is supersaturated, the antigen / antibody that is not bound to the colloidal gold or has a weaker binding ability is easy to compete with the antigen / antibody with a strong ability to bind to the colloidal gold for the substance to be tested, resulting in weak color intensity and low sensitivity of the product. Summary of the invention

[0005] In view of the above problems, the present invention provides a method for labeling recombinant human immunodeficiency virus antigen with colloidal gold, which can ensure the stability of the reagent strip and reduce the amount of antigen / antibody to be labeled, and avoid the occurrence of non-specific reactions due to vacant sites on the surface of the colloidal gold, thereby ultimately improving the color intensity and sensitivity of the product.

[0006] Also provided is a colloidal gold labeled human immunodeficiency virus recombinant antigen reagent strip, which has high detection sensitivity and good color development intensity.

[0007] Also provided is a kit for labeling human immunodeficiency virus recombinant antigen with colloidal gold, which is convenient to use and simple to operate.

[0008] In order to solve the above problems, the technical solution adopted by the present invention is as follows: a method for labeling human immunodeficiency virus recombinant antigen with colloidal gold, comprising the following steps: (1) preparing colloidal gold solution; (2) adjusting the pH value of the prepared colloidal gold solution to 6.0; (3) Add an appropriate amount of BSA-1 solution at one time; (4) adjusting the pH value of the liquid obtained in step (3) to 7.0-7.5; (5) Add human immunodeficiency virus recombinant antigen at one time, the amount added is 55%-65% of the amount of saturated labeled human immunodeficiency virus recombinant antigen; (6) Add the final blocking agent BSA-2 solution to complete the labeling.

[0009] As an optimization scheme, the colloidal gold solution in step (1) is a nano-gold solution with a concentration of 0.4 parts per million prepared by a trisodium citrate reduction method.

[0010] As an optimization scheme, the preparation method of the colloidal gold solution in step (1) is: 1) Prepare chloroauric acid solution: dissolve 10 g chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light.

[0011] 2) Prepare trisodium citrate solution: weigh 1 g of trisodium citrate, dissolve it in 100 mL of ultrapure water at room temperature, and store it at 4°C.

[0012] 3) Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution. Wait for the liquid in the flask to change from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

[0013] As an optimization solution, potassium carbonate solution is used to adjust the pH value in steps (2) and (4).

[0014] The potassium carbonate solution was prepared as follows: 2.76 g of anhydrous potassium carbonate was weighed, dissolved in 100 mL of ultrapure water, and stored at 2-8°C.

[0015] As an optimization scheme, the BSA-1 solution is added for 2 seconds in step (3).

[0016] As an optimization scheme, the amount of BSA-1 solution added in step (3) is: 1 μL BSA-1 solution is added to every 1 mL of colloidal gold solution, and the reaction time is 5 min.

[0017] The BSA-1 solution was prepared by weighing 0.5 g of BSA, dissolving it in 100 mL of ultrapure water, and storing it at 2-8°C.

[0018] As an optimization scheme, the human immunodeficiency virus recombinant antigen is added for 2 seconds in step (5).

[0019] As an optimization scheme, the amount of human immunodeficiency virus recombinant antigen added in step (5) is: 11-13 μg human immunodeficiency virus recombinant antigen per 1 mL of colloidal gold solution, and the reaction time is 10 minutes.

[0020] As an optimization scheme, the blocking agent in step (6) is BSA-2 solution, the addition amount is 1 mL of BSA-2 solution per 100 mL of colloidal gold solution, and the reaction time is 10 min.

[0021] The preparation method of BSA-2 solution is as follows: weigh 10 g BSA, dissolve it in 100 mL ultrapure water, and store it at 2-8°C.

[0022] A reagent strip for labeling human immunodeficiency virus recombinant antigen, the preparation method is as follows: (1) Membrane coating Coating diluent formula: 0.01M pH7.4 PB solution, mass percentage concentration of 0.05% trehalose.

[0023] The test line and the quality control line were coated on the NC membrane from bottom to top.

[0024] (2) Preparation of gold pad Formula of gold complex solution: 0.1M pH8.5 Tris solution, 0.5% casein by mass percentage concentration, 5% trehalose by mass percentage concentration, 0.2% PVP40 by mass percentage concentration, and 0.5% TritonX-100 by mass percentage concentration.

[0025] A colloidal gold solution was prepared, and then the human immunodeficiency virus recombinant antigen and rabbit IgG polyclonal antibody were labeled using the above-mentioned labeling method; after labeling, the solution was centrifuged, concentrated with a gold complex solution, evenly spread on glass fiber, and placed in an oven for 12 hours to form a gold pad.

[0026] (3) Sample pad processing Sample pad treatment solution formula: 0.1M pH8.5 Tris solution, 0.5% casein, 5% trehalose, 0.2% PVP40, 0.5% TritonX-100, 0.1% NaN 3 .

[0027] The treatment liquid was evenly coated on the glass fiber and placed in an oven for 12 hours to prepare a sample pad.

[0028] (4) Assembly of the reagent strip Assemble the absorbent paper, NC membrane, gold pad, sample pad and PVC base plate in order and cut them into reagent strips.

[0029] A kit for marking human immunodeficiency virus recombinant antigens comprises a test card and a sample diluent. The test card comprises a card body and a card cover which are buckled together, and the above-mentioned reagent strip is arranged between the card body and the card cover.

[0030] The formula of sample diluent is: 0.1M pH8.5 Tris solution, 0.5% casein, 0.5% Tween20, 0.1% NaN 3 .

[0031] The present invention adopts the above technical solution and has the following advantages: The conventional labeling process is to first adjust the pH value of the colloidal gold solution to near the isoelectric point of the antigen / antibody to be labeled, then add a saturated amount of the antigen / antibody to be labeled, and finally block to end the reaction process. The advantage of this process is that it allows the colloidal gold solution to fully combine with the labeled protein to ensure the stability of the gold label solution; the disadvantage is that it will cause the labeled proteins to be densely arranged around the colloidal gold, resulting in charge repulsion between the labeled proteins, which ultimately affects the color intensity and sensitivity of the product.

[0032] The present invention first wraps a small amount of bovine serum albumin around the colloidal gold, then wraps a sufficient amount of labeled protein around the colloidal gold for reaction, and finally performs sealing to terminate the reaction process. The advantages of this process are that it can avoid the dense arrangement of labeled proteins around the colloidal gold to form a phenomenon of charge repulsion between the same proteins, and at the same time can reduce the amount of labeled protein added to ensure the stability of the reagent strip, and can also avoid the occurrence of non-specific reactions due to vacant sites on the surface of the colloidal gold, which can ultimately be reflected in the product and significantly improve the color intensity and sensitivity of the product.

[0033] The present invention will be further described below in conjunction with the embodiments. DETAILED DESCRIPTION

[0034] Example 1: A method for labeling a human immunodeficiency virus recombinant antigen, comprising the following steps: (1) Liquid preparation Chloroauric acid solution: Dissolve 10 g of chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light.

[0035] Trisodium citrate solution: Weigh 1 g of trisodium citrate, dissolve it in 100 mL of ultrapure water at room temperature, and store it at 4°C.

[0036] Potassium carbonate solution: Weigh 2.76 g of anhydrous potassium carbonate, dissolve in 100 mL of ultrapure water, and store at 2°C.

[0037] BSA-1 solution: Weigh 0.5 g BSA, dissolve in 100 mL ultrapure water, store at 2°C, and prepare before use.

[0038] BSA-2 solution: Weigh 10 g BSA, dissolve in 100 mL ultrapure water, store at 2°C, and prepare before use.

[0039] (2) Preparation of colloidal gold solution Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution, wait until the liquid in the flask changes from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

[0040] (3) Colloidal gold labeling First, adjust the pH value of the prepared colloidal gold solution to 6.0, then add 1 μL of BSA-1 solution to every 1 mL of colloidal gold solution and react for 5 minutes; then adjust the pH value of the above liquid to 7.0, then add 13 μg of human immunodeficiency virus recombinant antigen to every 1 mL of the above liquid and react for 10 minutes; finally, add the blocking agent BSA-2 solution, add 1 mL of BSA-2 solution to every 100 mL of colloidal gold solution, react for 10 minutes, and the labeling is completed.

[0041] The saturated addition amount of the human immunodeficiency virus recombinant antigen is 20 μg per 1 mL of colloidal gold solution, and the addition amount of the human immunodeficiency virus recombinant antigen in Example 1 is 65% of the saturated addition amount; the optimal labeling pH value of the human immunodeficiency virus recombinant antigen is 7.0-7.5, and the labeling pH value of the human immunodeficiency virus recombinant antigen in Example 1 is 7.0; the BSA-1 solution is added for 2 seconds; the human immunodeficiency virus recombinant antigen is added for 2 seconds.

[0042] Example 2: A method for labeling human immunodeficiency virus recombinant antigens, comprising the following steps: (1) Liquid preparation Chloroauric acid solution: Dissolve 10 g of chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light.

[0043] Trisodium citrate solution: Weigh 1 g of trisodium citrate, dissolve it in 100 mL of ultrapure water at room temperature, and store it at 4°C.

[0044] Potassium carbonate solution: Weigh 2.76 g of anhydrous potassium carbonate, dissolve in 100 mL of ultrapure water, and store at 8°C.

[0045] BSA-1 solution: weigh 0.5 g BSA, dissolve in 100 mL ultrapure water, store at 8°C, and prepare before use.

[0046] BSA-2 solution: Weigh 10 g BSA, dissolve in 100 mL ultrapure water, store at 8°C, and prepare before use.

[0047] (2) Preparation of colloidal gold solution Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution, wait until the liquid in the flask changes from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

[0048] (3) Colloidal gold labeling First, adjust the pH value of the prepared colloidal gold solution to 6.0, then add 1 μL of BSA-1 solution to every 1 mL of colloidal gold solution and react for 5 minutes; then adjust the pH value of the above liquid to 7.2, then add 13 μg of human immunodeficiency virus recombinant antigen to every 1 mL of the above liquid and react for 10 minutes; finally, add the blocking agent BSA-2 solution, add 1 mL of BSA-2 solution to every 100 mL of colloidal gold solution, react for 10 minutes, and the labeling is completed.

[0049] The saturated addition amount of the human immunodeficiency virus recombinant antigen is 20 μg per 1 mL of colloidal gold solution, and the addition amount of the human immunodeficiency virus recombinant antigen in Example 2 is 65% of the saturated addition amount; the optimal labeling pH value of the human immunodeficiency virus recombinant antigen is 7.0-7.5, and the labeling pH value of the human immunodeficiency virus recombinant antigen in Example 2 is 7.2; the BSA-1 solution is added for 2 seconds; the human immunodeficiency virus recombinant antigen is added for 2 seconds.

[0050] Example 3: A method for labeling human immunodeficiency virus recombinant antigen, the labeling method comprising the following steps: (1) Liquid preparation Chloroauric acid solution: Dissolve 10 g of chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light.

[0051] Trisodium citrate solution: Weigh 1 g of trisodium citrate, dissolve it in 100 mL of ultrapure water at room temperature, and store it at 4°C.

[0052] Potassium carbonate solution: Weigh 2.76 g of anhydrous potassium carbonate, dissolve in 100 mL of ultrapure water, and store at 5°C.

[0053] BSA-1 solution: weigh 0.5 g BSA, dissolve in 100 mL ultrapure water, store at 4°C, and prepare before use.

[0054] BSA-2 solution: Weigh 10 g BSA, dissolve in 100 mL ultrapure water, store at 6°C, and prepare before use.

[0055] (2) Preparation of colloidal gold solution Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution, wait until the liquid in the flask changes from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

[0056] (3) Colloidal gold labeling First, adjust the pH value of the prepared colloidal gold solution to 6.0, then add 1 μL of BSA-1 solution to every 1 mL of colloidal gold solution and react for 5 minutes; then adjust the pH value of the above liquid to 7.5, then add 11 μg of human immunodeficiency virus recombinant antigen to every 1 mL of the above liquid and react for 10 minutes; finally, add the blocking agent BSA-2 solution, add 1 mL of BSA-2 solution to every 100 mL of colloidal gold solution, react for 10 minutes, and the labeling is completed.

[0057] The saturated addition amount of the human immunodeficiency virus recombinant antigen is 20 μg per 1 mL of colloidal gold solution, and the addition amount of the human immunodeficiency virus recombinant antigen in Example 3 is 55% of the saturated addition amount; the optimal labeling pH value of the human immunodeficiency virus recombinant antigen is 7.0-7.5, and the labeling pH value of the human immunodeficiency virus recombinant antigen in Example 3 is 7.5; the BSA-1 solution is added for 2 seconds; the human immunodeficiency virus recombinant antigen is added for 2 seconds.

[0058] Example 4: A method for labeling human immunodeficiency virus recombinant antigen, the labeling method comprising the following steps: (1) Liquid preparation Chloroauric acid solution: Dissolve 10 g of chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light.

[0059] Trisodium citrate solution: Weigh 1 g of trisodium citrate, dissolve it in 100 mL of ultrapure water at room temperature, and store it at 4°C.

[0060] Potassium carbonate solution: Weigh 2.76 g of anhydrous potassium carbonate, dissolve in 100 mL of ultrapure water, and store at 2°C.

[0061] BSA-1 solution: weigh 0.5 g BSA, dissolve in 100 mL ultrapure water, store at 8°C, and prepare before use.

[0062] BSA-2 solution: Weigh 10 g BSA, dissolve in 100 mL ultrapure water, store at 8°C, and prepare before use.

[0063] (2) Preparation of colloidal gold solution Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution, wait until the liquid in the flask changes from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

[0064] (3) Colloidal gold labeling First, adjust the pH value of the prepared colloidal gold solution to 6.0, then add 1 μL of BSA-1 solution to every 1 mL of colloidal gold solution and react for 5 minutes; then adjust the pH value of the above liquid to 7.0, then add 12 μg of human immunodeficiency virus recombinant antigen to every 1 mL of the above liquid and react for 10 minutes; finally, add the blocking agent BSA-2 solution, add 1 mL of BSA-2 solution to every 100 mL of colloidal gold solution, react for 10 minutes, and the labeling is completed.

[0065] The saturated addition amount of the human immunodeficiency virus recombinant antigen is 20 μg per 1 mL of colloidal gold solution, and the addition amount of the human immunodeficiency virus recombinant antigen in Example 4 is 60% of the saturated addition amount; the optimal labeling pH value of the human immunodeficiency virus recombinant antigen is 7.0-7.5, and the labeling pH value of the human immunodeficiency virus recombinant antigen in Example 4 is 7.0; the BSA-1 solution is added for 2 seconds; the human immunodeficiency virus recombinant antigen is added for 2 seconds.

[0066] Example 5: A method for labeling human immunodeficiency virus recombinant antigen, the labeling method comprising the following steps: (1) Liquid preparation Chloroauric acid solution: Dissolve 10 g of chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light.

[0067] Trisodium citrate solution: Weigh 1 g of trisodium citrate, dissolve it in 100 mL of ultrapure water at room temperature, and store it at 4°C.

[0068] Potassium carbonate solution: Weigh 2.76 g of anhydrous potassium carbonate, dissolve in 100 mL of ultrapure water, and store at 5°C.

[0069] BSA-1 solution: Weigh 0.5 g BSA, dissolve in 100 mL ultrapure water, store at 2°C, and prepare before use.

[0070] BSA-2 solution: Weigh 10 g BSA, dissolve in 100 mL ultrapure water, store at 8°C, and prepare before use.

[0071] (2) Preparation of colloidal gold solution Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution, wait until the liquid in the flask changes from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

[0072] (3) Colloidal gold labeling First, adjust the pH value of the prepared colloidal gold solution to 6.0, then add 1 μL of BSA-1 solution to every 1 mL of colloidal gold solution and react for 5 minutes; then adjust the pH value of the above liquid to 7.5, then add 12 μg of human immunodeficiency virus recombinant antigen to every 1 mL of the above liquid and react for 10 minutes; finally, add the blocking agent BSA-2 solution, add 1 mL of BSA-2 solution to every 100 mL of colloidal gold solution, react for 10 minutes, and the labeling is completed.

[0073] The saturated addition amount of the human immunodeficiency virus recombinant antigen is 20 μg per 1 mL of colloidal gold solution, and the addition amount of the human immunodeficiency virus recombinant antigen in Example 5 is 60% of the saturated addition amount; the optimal labeling pH value of the human immunodeficiency virus recombinant antigen is 7.0-7.5, and the labeling pH value of the human immunodeficiency virus recombinant antigen in Example 5 is 7.5; the BSA-1 solution is added for 2 seconds; the human immunodeficiency virus recombinant antigen is added for 2 seconds.

[0074] Example 6: A reagent strip labeled with human immunodeficiency virus recombinant antigen, the preparation method of the reagent strip is as follows: (1) Membrane coating Coating diluent formula: 0.01M pH7.4 PB solution, mass percentage concentration of 0.05% trehalose.

[0075] The test line and the quality control line were coated on the NC membrane from bottom to top.

[0076] (2) Preparation of gold pad Formula of gold complex solution: 0.1M pH8.5 Tris solution, 0.5% casein by mass percentage concentration, 5% trehalose by mass percentage concentration, 0.2% PVP40 by mass percentage concentration, and 0.5% TritonX-100 by mass percentage concentration.

[0077] A colloidal gold solution was prepared, and then the human immunodeficiency virus recombinant antigen and rabbit IgG polyclonal antibody were labeled using the labeling method of any one of Examples 1-5; after labeling, the solution was centrifuged, concentrated with a gold complex solution, evenly spread on glass fiber, and placed in an oven for 12 hours to form a gold pad.

[0078] (3) Sample pad processing Sample pad treatment solution formula: 0.1M pH8.5 Tris solution, 0.5% casein, 5% trehalose, 0.2% PVP40, 0.5% TritonX-100, 0.1% NaN 3 .

[0079] The treatment liquid was evenly coated on the glass fiber and placed in an oven for 12 hours to prepare a sample pad.

[0080] (4) Assembly of the reagent strip Assemble the absorbent paper, NC membrane, gold pad, sample pad and PVC base plate in order and cut them into reagent strips.

[0081] Example 7: A kit for labeling human immunodeficiency virus recombinant antigen, the kit comprising a test card and a sample diluent, the test card comprising a card body and a card cover that are interlocked, and a reagent strip of Example 6 is disposed between the card body and the card cover.

[0082] The formula of sample diluent is: 0.1M pH8.5 Tris solution, 0.5% casein, 0.5% Tween20, 0.1% NaN 3 .

[0083] The experimental data of labeling human immunodeficiency virus recombinant antigen are as follows: In order to illustrate the advantages of the technical solution adopted in this patent, we used it in the immunochromatography anti-human immunodeficiency virus antibody detection reagent and compared it with the conventional labeling method.

[0084] The preparation method of colloidal gold reagent strips is as follows: (1) Membrane coating Coating diluent formula: 0.01M pH7.4 PB solution, mass percentage concentration of 0.05% trehalose.

[0085] The test line human immunodeficiency virus recombinant antigen and the quality control line rabbit IgG polyclonal antibody were coated on the NC membrane from bottom to top, with the coating concentrations of 1.5 mg / mL and 2.0 mg / mL respectively.

[0086] (2) Preparation of gold pad Formula of gold complex solution: 0.1M pH8.5 Tris solution, 0.5% casein by mass percentage concentration, 5% trehalose by mass percentage concentration, 0.2% PVP40 by mass percentage concentration, and 0.5% TritonX-100 by mass percentage concentration.

[0087] A colloidal gold solution was prepared, and then human immunodeficiency virus recombinant antigen and rabbit IgG polyclonal antibody were labeled according to the conventional labeling method and the labeling method of any one of Examples 1-5; after labeling, the solution was centrifuged, concentrated with a gold complex solution, evenly spread on glass fiber, and placed in an oven for 12 hours to prepare a gold pad.

[0088] The conventional labeling method is: first make a ratio to determine the optimal pH value and saturated protein amount for colloidal gold labeling, then adjust the colloidal gold to the optimal pH value with potassium carbonate solution, add the protein to be labeled according to the saturated protein amount, and react for 10 minutes; finally, add 1 mL of 10% BSA solution by mass percentage for every 100 mL for blocking, and the labeling is completed.

[0089] (3) Sample pad processing Sample pad treatment solution formula: 0.1M pH8.5 Tris solution, 0.5% casein, 5% trehalose, 0.2% PVP40, 0.5% TritonX-100, 0.1% NaN 3 .

[0090] The treatment liquid was evenly coated on the glass fiber and placed in an oven for 12 hours to prepare a sample pad.

[0091] (4) Assembly and testing of test strips Assemble the absorbent paper, NC membrane, gold pad, sample pad and PVC base plate in order and cut them into reagent strips.

[0092] The experiments were conducted to compare the differences in potency, sensitivity, specificity and stability of anti-human immunodeficiency virus antibody detection products made by different labeling methods.

[0093] The specific experimental data are as follows: Note: "-" indicates a negative test result, "+" indicates a positive test result, and the more "+" there are, the stronger the color intensity and the higher the titer.

[0094] Potency comparison:

[0095] Sensitivity comparison:

[0096] Specificity:

[0097] Stability comparison:

[0098] From the above data, it can be seen that the method of the present invention for labeling human immunodeficiency virus recombinant antigens has significantly improved the titer and sensitivity while ensuring specificity and stability compared with conventional labeling methods.

[0099] It should be noted that the above-described embodiments of the present invention do not limit the protection scope of the present invention. Any technical solution obtained by equivalent replacement or equivalent transformation should be included in the protection scope of the present invention.

Claims

1. A method for labeling human immunodeficiency virus recombinant antigen with colloidal gold, characterized in that: The following steps are involved: (1) preparing colloidal gold solution; (2) adjusting the pH value of the prepared colloidal gold solution to 6.0; (3) Add an appropriate amount of BSA-1 solution at one time; (4) adjusting the pH value of the liquid obtained in step (3) to 7.0-7.5; (5) Add human immunodeficiency virus recombinant antigen at one time, the amount added is 55%-65% of the amount of saturated labeled human immunodeficiency virus recombinant antigen; (6) Add the final blocking agent BSA-2 solution to complete the labeling.

2. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 1, characterized in that: The preparation method of the colloidal gold solution in step (1) is: 1) Prepare chloroauric acid solution: dissolve 10 g chloroauric acid in ultrapure water, dilute to 1000 mL after complete dissolution, and store at 4°C away from light; 2) Prepare trisodium citrate solution: weigh 1 g trisodium citrate, dissolve in 100 mL ultrapure water at room temperature, and store at 4°C; 3) Add 4 mL of chloroauric acid solution and 96 mL of ultrapure water into a three-necked flask, heat to boiling, then add 5 mL of trisodium citrate solution. Wait for the liquid in the flask to change from blue-purple to wine red, react for 20 minutes, cool naturally, and store at room temperature away from light.

3. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 2, characterized in that: In steps (2) and (4), a potassium carbonate solution is used to adjust the pH value. The potassium carbonate solution is prepared by weighing 2.76 g of anhydrous potassium carbonate, dissolving it in 100 mL of ultrapure water, and storing it at 2-8°C.

4. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 3, characterized in that: In step (3), the BSA-1 solution is added for 2 seconds, the amount of BSA-1 solution added is: 1 μL BSA-1 solution is added for every 1 mL of colloidal gold solution, and the reaction time is 5 minutes.

5. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 4, characterized in that: The BSA-1 solution was prepared by weighing 0.5 g of BSA, dissolving it in 100 mL of ultrapure water, and storing it at 2-8°C.

6. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 5, characterized in that: In the step (5), the human immunodeficiency virus recombinant antigen is added for 2 seconds, the amount of human immunodeficiency virus recombinant antigen added is: 11-13 μg human immunodeficiency virus recombinant antigen is added per 1 mL of colloidal gold solution, and the reaction time is 10 minutes.

7. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 6, characterized in that: In step (6), the blocking agent is BSA-2 solution, the amount added is 1 mL of BSA-2 solution per 100 mL of colloidal gold solution, and the reaction time is 10 min.

8. The method for labeling human immunodeficiency virus recombinant antigen with colloidal gold according to claim 7, characterized in that: The BSA-2 solution was prepared by weighing 10 g of BSA, dissolving it in 100 mL of ultrapure water, and storing it at 2-8°C.

9. A reagent strip for labeling human immunodeficiency virus recombinant antigen, characterized in that: The preparation method is as follows: (1) Membrane coating Encapsulation diluent formula: 0.01M pH7.4 PB solution, mass percentage concentration of 0.05% trehalose; Coat the test line and quality control line on the NC membrane from bottom to top; (2) Preparation of gold pad Formula of gold complex solution: 0.1M pH8.5 Tris solution, 0.5% casein by mass percentage, 5% trehalose by mass percentage, 0.2% PVP40 by mass percentage, and 0.5% TritonX-100 by mass percentage; A colloidal gold solution is prepared, and then the human immunodeficiency virus recombinant antigen and rabbit IgG polyclonal antibody are labeled by the above-mentioned labeling method; after labeling, the mixture is centrifuged, concentrated with a gold complex solution, evenly spread on glass fiber, and placed in an oven for 12 hours to form a gold pad; (3) Sample pad processing Sample pad treatment solution formula: 0.1M pH8.5 Tris solution, 0.5% casein by mass percentage, 5% trehalose by mass percentage, 0.2% PVP40 by mass percentage, 0.5% TritonX-100 by mass percentage, and 0.1% NaN3 by mass percentage; The treatment liquid was evenly coated on the glass fiber and placed in an oven for 12 hours to prepare a sample pad; (4) Assembly of the reagent strip Assemble the absorbent paper, NC membrane, gold pad, sample pad and PVC base plate in order and cut them into reagent strips.

10. A kit for labeling human immunodeficiency virus recombinant antigen, characterized in that: The invention comprises a test card and a sample diluent, wherein the test card comprises a card cover and a card body which are interlocked with each other, and a reagent strip according to claim 9 is arranged between the card cover and the card body, and the formula of the sample diluent is: 0.1M pH8.5 Tris solution, 0.5% casein by mass percentage concentration, 0.5% Tween20 by mass percentage concentration, and 0.1% NaN3 by mass percentage concentration.

Citation Information

Patent Citations

  • Method, reagent strip and kit for labeling typhoid salmonella recombinant antigen by colloidal gold

    CN112630421A

  • Method, reagent strip and kit for labeling anti-plasmodium vivax pLDH monoclonal antibody

    CN112858677A

  • Preparation method of test strip for improving human immunodeficiency virus antibody detection and kit

    CN115541882A

  • Simultaneous diagnosis kit for HIV type 1, 2 and O using immunochromatographic assay and simultaneous diagnosis method using the same

    KR1020180025830A